Is Ocular Therapeutix (OCUL) Still Undervalued Or Is AXPAXLI Hope Already Priced In?
Ocular Therapeutix Inc OCUL
$8.17
▼ -3.54%
($-0.30)
⬇️ Below Yest. Low
📅 Earnings This Week
Open
$8.44
Prev Close
$8.47
Day Range
$8.15 – $8.56
52W Range
$6.23 – $16.44
Market Cap
$1.79B
Beta
0.92
EPS (TTM)
$-1.46
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2014-07-25 |
| Shares Out. | 218,960,000 |
| Website | ocutx.com/ ↗ |
| Phone | 13026744089 |
| Employees | 325 |
| Revenue | $10.8M |
| Gross Profit | $9.5M |
| Net Income | -$88.6M |
| Free Cash Flow | -$240.9M |
| Total Assets | $732.5M |
| Total Liabilities | $151.0M |
| Equity | $581.6M |
About Ocular Therapeutix Inc
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Ocular Therapeutix Inc is a publicly traded company under the ticker symbol OCUL on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-07-01)